RxDoctor Payments Data

Alyssa Naldoza, PA

Physician Assistant · Norfolk, VANPI 1982311445

Payments from drug & device makers

$3,806in general payments, 2019–2025

Across 150 payments — averaging $25.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$750
  • Johnson & Johnson$486
  • Novartis$342
  • AstraZeneca$257
  • Novo Nordisk$235
  • Amgen$232
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$2898%
  • Food & beverage$3,48592%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,806 in reported general payments places this provider in the 90th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$91,890
Medicare patients
480
Services billed
988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$84,580
EntrestoSacubitril/Valsartan74$83,662
FarxigaDapagliflozin Propanediol81$77,522
Repatha SureclickEvolocumab57$59,904
VascepaIcosapent Ethyl49$35,436
XareltoRivaroxaban20$18,067
JardianceEmpagliflozin17$16,269
Metoprolol Succinate120$1,999
Carvedilol108$1,012
Atorvastatin Calcium104$884
Flecainide Acetate17$855
Bumetanide12$832
Telmisartan11$769
Potassium Chloride21$654
Furosemide81$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$229$84,58085 claims
NovartisEntresto$342$83,66274 claims
AstraZenecaFarxiga$257$77,52281 claims
Johnson & JohnsonXarelto$486$18,06720 claims
Boehringer IngelheimJardiance$108$16,26917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →